Fresh from leading at the forefront of the pandemic, the life sciences industry now comes together and reacts to the uncertainty of the post-crisis market. Though the impact will be transient in the long-term, the full effects of the crisis should be contrasted across different segments of the life sciences sector. There will be strong opportunities post the crisis for companies with solid foundations.

The life sciences sector has moved from an in-house model to an increased reliance on partnering for R&D, manufacturing and logistics services, as well as for product acquisitions. During our upcoming webinar, attendees can expect to learn:

• What specific deal trends and investment opportunities are emerging from the crisis?
• How is deal making impacted?
• What does greater investment into research and development mean for the next generation of scientific discovery?

This collaborative series is exclusively tailored to senior leaders and investors in the global health and life sciences industry.